Optical coherence tomography (OCT) has fundamentally changed the landscape of retinal imaging and disease management. By providing cross-sectional, micron-level detail of retinal architecture, this non-invasive technique allows ophthalmologists to diagnose, monitor, and guide treatment for a wide spectrum of retinal conditions with unprecedented precision. Over the past decade, rapid technological innovations have expanded OCT’s capabilities beyond structural imaging into functional and angiographic domains, further strengthening its role in clinical practice. This article reviews the core principles of OCT, explores recent advances that have pushed the boundaries of the technology, and examines how these developments are reshaping the management of retinal diseases.

What Is Optical Coherence Tomography?

OCT is an imaging modality that employs low-coherence interferometry to generate high-resolution, two-dimensional and three-dimensional images of biological tissues. It operates on a principle analogous to ultrasound, but uses near-infrared light instead of sound waves. The time delay and intensity of backscattered light from different tissue layers are measured to construct detailed cross-sectional images. Because the speed of light is extremely high, OCT systems rely on interferometric techniques—typically using a Michelson interferometer—to compare the light reflected from the sample with a reference beam.

In the context of ophthalmology, OCT provides visualization of the retina’s layered structure, including the nerve fiber layer, ganglion cell complex, inner and outer photoreceptor segments, retinal pigment epithelium (RPE), and choroid. The axial resolution of modern OCT systems ranges from 1 to 10 micrometers, which is sufficient to resolve individual retinal layers. This capability enables clinicians to detect pathological changes such as intraretinal fluid, subretinal fluid, drusen, and RPE atrophy long before they become apparent on clinical examination.

Since its introduction in the early 1990s, OCT technology has evolved through several generations: time-domain OCT (TD-OCT), spectral-domain OCT (SD-OCT), and swept-source OCT (SS-OCT). Each advancement has brought improvements in imaging speed, resolution, and penetration depth. Today, OCT is considered a standard of care for managing conditions like age-related macular degeneration (AMD), diabetic macular edema (DME), and glaucoma.

Recent Technological Advances in OCT

Innovations in OCT hardware, software, and signal processing have dramatically expanded its utility. Below are the most impactful recent developments.

Swept-Source OCT (SS-OCT)

SS-OCT uses a tunable laser light source that rapidly sweeps across a range of wavelengths, typically centered around 1050 nm or 1060 nm. This longer wavelength offers two distinct advantages: reduced light scattering in the RPE and deeper penetration into the choroid. SS-OCT systems can achieve imaging speeds exceeding 100,000 A-scans per second, allowing for dense volumetric scans and reducing motion artifacts. The deeper penetration enables visualization of the choroid, choroidal vasculature, and the sclera, which is particularly valuable for diagnosing and monitoring conditions such as central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal nevi.

Furthermore, SS-OCT’s high speed facilitates wide-field imaging (up to 12 mm × 12 mm in a single scan), providing a more comprehensive view of the posterior pole. This is especially useful for assessing peripheral retinal pathology in diabetic retinopathy and retinal vein occlusions.

Ultra-High-Resolution OCT (UHR-OCT)

By employing broad bandwidth light sources, UHR-OCT achieves axial resolutions on the order of 1–3 micrometers—significantly finer than the 5–10 micrometers of conventional SD-OCT. This level of resolution permits visualization of individual photoreceptor layers, the external limiting membrane (ELM), the ellipsoid zone (EZ), and the interdigitation zone. Detecting subtle disruptions in these structures can provide early biomarkers of disease progression and response to therapy. For example, the integrity of the EZ line on UHR-OCT has been correlated with visual acuity outcomes in patients undergoing anti-VEGF therapy for neovascular AMD.

UHR-OCT is also valuable in inherited retinal dystrophies, where it can reveal loss of photoreceptor layers before electroretinogram changes become evident. However, the trade-off for high resolution is often slower imaging speeds and a more limited depth range, which continues to be an area of active research.

OCT Angiography (OCTA)

OCTA represents one of the most transformative advances in retinal imaging. Unlike traditional fluorescein or indocyanine green angiography, OCTA does not require intravenous dye injection. Instead, it detects motion contrast from flowing red blood cells by comparing repeated B-scans at the same location. Algorithms such as split-spectrum amplitude decorrelation angiography (SSADA) and optical microangiography (OMG) generate depth-resolved maps of retinal and choroidal vasculature.

OCTA allows for en face and cross-sectional visualization of the superficial and deep capillary plexuses in the retina, as well as the choriocapillaris. This has revolutionized the evaluation of diabetic retinopathy, where OCTA can identify capillary non-perfusion, microaneurysms, and neovascularization earlier than conventional angiography. In AMD, OCTA delineates type 1 (sub-RPE) and type 2 (subretinal) choroidal neovascularization without the risk of dye leakage obscuring the boundaries. The technology also demonstrates utility in assessing choroidal ischemia in central serous chorioretinopathy and the effects of anti-VEGF therapy on vessel density.

Recent advances in OCTA include wide-field montages, quantitative metrics (vessel density, fractal dimension, foveal avascular zone area), and artifact reduction algorithms. These improvements are pushing OCTA closer to replacing traditional angiography for many clinical indications.

Artificial Intelligence and Machine Learning Integration

The wealth of data generated by modern OCT and OCTA systems has spurred the development of AI-based tools for image analysis, automated segmentation, and disease classification. Deep learning algorithms can now detect and quantify intraretinal and subretinal fluid, identify drusen volume, segment retinal layers, and estimate choroidal thickness with high accuracy. Some systems are being validated for diagnosing diabetic retinopathy and AMD from OCT images alone, potentially enabling telemedicine screening in underserved populations.

AI also enhances OCTA interpretation by removing projection artifacts and automatically identifying regions of capillary dropout. Future applications may include predicting treatment response—for example, determining which DME eyes require more frequent anti-VEGF injections based on baseline OCT biomarkers. As AI becomes more integrated into clinical workflows, it promises to augment rather than replace the clinician’s expertise, improving diagnostic consistency and efficiency.

Impact on Retinal Disease Management

The technological advances described above have had a profound impact on how retinal specialists diagnose and manage diseases across the spectrum. Below we discuss specific applications.

OCT has become indispensable for both dry (nonexudative) and wet (exudative) AMD. Structural OCT enables the detection of drusen, subretinal drusenoid deposits (reticular pseudodrusen), and geographic atrophy (GA). Quantitative measurement of GA area progression over time, using automated algorithms, provides objective endpoints for clinical trials assessing emerging therapies for dry AMD. OCTA reveals the presence and morphology of choroidal neovascularization (CNV) in exudative AMD, allowing for earlier treatment and monitoring of responses. Recent work using OCT to identify hyperreflective foci and outer retinal tubulations as prognostic biomarkers is helping to personalize treatment intervals.

Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)

In DR, OCT is used to grade the severity of macular edema by measuring central subfield thickness and detecting intraretinal cysts and subretinal fluid. OCTA has added a new dimension by quantifying the extent of capillary non-perfusion in the macular and peripapillary regions. This information correlates with the risk of progression to proliferative DR and visual outcomes after panretinal photocoagulation. For DME, OCT biomarkers such as presence of hyperreflective foci, disruption of the ELM and EZ, and posterior vitreous attachment status help guide the choice between anti-VEGF therapy, corticosteroids, or laser.

Retinal Vein Occlusion (RVO)

OCT and OCTA are essential for managing RVO. Structural OCT detects macular edema and identifies ischemia using the disorganization of retinal inner layers (DRIL) sign. OCTA can localize areas of capillary dropout in the deep capillary plexus that are not well visualized by fluorescein angiography. Recent studies show that the foveal avascular zone area measured on OCTA after treatment correlates with final visual acuity, helping clinicians set realistic expectations and decide on retreatments.

Glaucoma

While glaucoma is an optic neuropathy, OCT of the retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) is a cornerstone of its diagnosis and monitoring. Spectral-domain OCT provides reproducible measurements of RNFL thickness, which can detect progression years before visual field loss becomes evident. Newer developments such as OCTA of the optic nerve head and peripapillary region show promise in evaluating vascular contributions to glaucoma pathogenesis. The combination of structural and vascular OCT parameters may improve risk stratification in glaucoma suspects.

Inherited Retinal Dystrophies (IRDs)

In conditions like retinitis pigmentosa, Stargardt disease, and achromatopsia, UHR-OCT can assess the integrity of photoreceptor layers, helping to classify disease severity and identify potential candidates for gene therapy. For example, the retention of a preserved ellipsoid zone in the fovea is a favorable prognostic factor for the success of gene replacement therapy. OCTA also reveals secondary vascular changes, such as constriction of retinal vessels and choriocapillaris atrophy, which may serve as biomarkers of disease progression.

Future Directions in OCT Technology

The pace of innovation in OCT shows no signs of slowing. Several emerging trends are likely to shape the next decade of retinal imaging.

Adaptive Optics OCT

Combining adaptive optics (AO) with OCT corrects for ocular aberrations, enabling lateral resolution on the order of a few micrometers and allowing visualization of individual photoreceptor cells. AO-OCT has already been used to study cone density in vivo in conditions like albinism and choroideremia. While still largely a research tool, its translation into clinical practice could open new avenues for early diagnosis and treatment monitoring at the cellular level.

Ultra-Widefield OCT

Current wide-field OCT systems cover approximately 12 mm × 12 mm, but prototype ultra-widefield OCT can image up to 23–24 mm, encompassing the posterior pole and mid-periphery. This is particularly valuable for assessing peripheral retinal pathology in conditions such as uveitis, retinoschisis, and diabetic retinopathy. Ultra-widefield OCT may also improve the detection of subclinical CNV or asymptomatic tractional membranes.

Multimodal Imaging Integration

Integrating OCT with other imaging modalities—such as autofluorescence, near-infrared reflectance, and fundus photography—in a single device allows for comprehensive assessment without changing instruments. Deep learning algorithms that fuse data from multiple channels may provide a more nuanced classification of disease stages and better prediction of visual outcomes.

Handheld and Portable OCT Systems

Miniaturization of OCT components has led to the development of handheld probes and portable devices. These are particularly beneficial for imaging pediatric patients, immobilized adults, or patients in rural or mobile clinics. Recent handheld SD-OCT and SS-OCT systems achieve image quality comparable to tabletop units, opening the door for point-of-care retinal screening.

Artificial Intelligence–Guided Decision Support

Beyond image analysis, AI could soon provide real-time decision support during OCT acquisition. For example, an algorithm might suggest that a patient’s scan reveals early signs of AMD and recommend a shorter follow-up interval. Such systems are already being tested in clinical trials for diabetic retinopathy screening and neovascular activity detection. The integration of OCT with electronic health records and treatment databases will further enable personalized medicine based on large-scale real-world data.

Conclusion

Optical coherence tomography has evolved from a niche research tool into a cornerstone of retinal disease management. Advances in swept-source technology, ultra-high-resolution imaging, OCT angiography, and artificial intelligence are expanding the boundaries of what can be visualized and quantified in the living human retina. These innovations translate directly into earlier diagnoses, more precise monitoring, and tailored therapeutics for conditions ranging from AMD and diabetic retinopathy to glaucoma and inherited dystrophies. As the technology continues to mature, its integration into routine clinical workflows will only deepen, ultimately improving visual outcomes and quality of life for patients worldwide.

External References: